As Ozempic's patent expiry approaches, Indian API manufacturers are strategically positioning themselves to meet exploding global demand for semaglutide, the breakthrough diabetes and obesity treatment.
The pharmaceutical industry is focusing on critical preparation areas to ensure successful market entry once patents expire, with supply chain security emerging as the primary challenge.
Strategic Preparation for Market Entry
Hari Kiran Chereddi, MD & CEO of HRV Pharma & New Horizon Global Pharma (NHG Pharma), emphasizes the critical preparation requirements:
"Securing consistent, high-quality starting materials and scaling up purification... that's why API players are preparing well before patent expiry."
Hari Kiran Chereddi, MD & CEO, HRV Pharma & New Horizon Global Pharma
Beyond Patents: Global Healthcare Impact
The opportunity extends beyond commercial considerations to fundamental healthcare access:
"This isn't just about patents, it's about ensuring millions have access to life-changing diabetes treatments."
Hari Kiran Chereddi, MD & CEO, HRV Pharma & New Horizon Global Pharma
Extensive Media Coverage
This development has received widespread international media attention:
- Bloomberg
- The Economic Times
- Financial Post
- Chemical Industry Digest
- Business Upturn
- MSN
- National Post
The industry's proactive approach to semaglutide manufacturing preparation demonstrates commitment to both commercial opportunity and global healthcare accessibility.
